A phase II study of Gleevac [imatinib] in patients with recurrent platinum-resistant, taxane-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2012
At a glance
- Drugs Imatinib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Mar 2012 Actual patients number is 73 as reported by ClinicalTrials.gov.
- 16 Mar 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
- 16 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.